H.C. Wainwright assumed coverage of 60 Degrees Pharmaceuticals (SXTP) with a Buy rating and $6 price target The firm says 60 Degrees is “flying under the radar with investors.” Tafenoquine is a differentiated, FDA approved product that is already on the market and has demonstrated “impressive” initial clinical activity in babesiosis, the analyst tells investors in a research note.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SXTP:
- 60 Degrees Pharmaceuticals reports Q3 EPS (66c) vs. ($4.65) last year
- SXTP Upcoming Earnings Report: What to Expect?
- 60 Degrees Pharmaceuticals Advances Tafenoquine Study for Chronic Babesiosis
- 60 Degrees announces first patient completed regimen in babesiosis trial
- 60 Degrees Pharmaceuticals Holds Annual Stockholders Meeting